Latest Organovo Holdings Inc. Stories
SAN DIEGO, April 25, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQX: ONVO) ("Organovo"), a creator and manufacturer of functional, three-dimensional human tissues for medical research and therapeutic applications, has been invited to present at the 12th Annual Needham Healthcare Conference, which will be held in New York April 30 through May 1, 2013. Organovo's Chairman and Chief Executive Officer, Keith Murphy, will present on May 1st, at 3:00 p.m. Needham & Company's 12th...
SAN DIEGO, April 22, 2013 /PRNewswire/ --Organovo Holdings, Inc. (OTCQX ONVO) ("Organovo"), a creator and manufacturer of functional, three-dimensional human tissues for medical research and therapeutic applications, presented at the 2013 Experimental Biology conference in Boston, Massachusetts data on the company's in vitro three-dimensional liver. "We have achieved excellent function in a fully cellular 3D human liver tissue. With Organovo's 3D bioprinted liver tissues, we have...
SAN DIEGO, April 10, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQX ONVO) ("Organovo"), a creator and manufacturer of functional, three-dimensional human tissues for medical research and therapeutic applications, today provided a summary of the data it plans to present at the upcoming 2013 Experimental Biology conference in Boston, Massachusetts, from April 20-24. The company plans multiple presentations at the conference. Dr. Sharon Presnell, Organovo chief technology...
SAN DIEGO, April 3, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQX: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, announced today that the Company's Board of Directors has approved a fiscal year-end change from December 31st to March 31st, beginning on March 31, 2013. With this change, Organovo's current fiscal year began on April 1st and will end on March 31st each year. The change in fiscal year is in...
SAN DIEGO, Feb. 20, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQX: ONVO) ("Organovo"), a creator and manufacturer of functional, three-dimensional human tissues for medical research and therapeutic applications, and ZenBio Inc., a leading provider of advanced cell-based solutions and services, are partnering to produce three-dimensional human tissues for drug discovery and advanced tissue therapies. ZenBio will provide unique, validated cellular inputs for use by Organovo with...
SAN DIEGO, Feb. 5, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQX: ONVO) ("Organovo"), a creator and manufacturer of functional, three-dimensional human tissues for medical research and therapeutic applications, today announced its intention to redeem two classes of outstanding warrants initially issued to investors participating in private placement financings in 2011 and 2012. The warrant redemption will raise non-dilutive capital, enable Organovo to significantly improve...
SAN DIEGO, Jan. 30, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQX: ONVO) ("Organovo"), a creator and manufacturer of functional, three-dimensional human tissues for medical research and therapeutic applications, and the Knight Cancer Institute at Oregon Health & Science University (OHSU), a national leader in translational oncology research, have formed a collaboration to develop more clinically predictive in vitro three dimensional cancer models which will ultimately...
NEW YORK, January 24, 2013 /PRNewswire/ -- Fourth-quarter revenues reported by tech giants IBM and AMD gave the markets a boost yesterday. IBM rallied more than 4% to hit $204.72 as their profit forecast beat analyst estimates. AMD, the second-biggest maker of processors for personal computers, also beat analyst estimates and rose more than 10% to hit $2.73. Apple reported weaker than expected first-quarter sales, dragging the stock down more than 10% after hours....
SAN DIEGO, Dec. 18, 2012 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQX: ONVO) ("Organovo"), a creator and manufacturer of functional, three-dimensional human tissues for medical research and therapeutic applications, is working together with researchers at Autodesk, Inc., the leader in cloud-based design and engineering software, to create the first 3D design software for bioprinting. The software, which will be used to control Organovo's NovoGen MMX bioprinter, will represent a...
NEW YORK, Dec. 10, 2012 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQX: ONVO) the San Diego-based regenerative medicine company focused on using its breakthrough NovoGen 3D human tissue printing technology to create tissue on demand for medical research and therapeutic applications, today announced that Keith Murphy, CEO, will present at RetailInvestorConferences.com. LINK: www.retailinvestorconferences.com > red "register/ watch event now" button Organovo Holdings, Inc.'s...
